Following ARK Invest: Quick move into position! PayPay's IPO day sees a massive purchase of 270,000 shares; trimmed Circle on rallies.

On Thursday Eastern Time, the three major U.S. stock indexes collectively closed lower. Following the first statement by Iran's new Supreme Leader, hopes for a swift easing of tensions were dashed, triggering a surge in crude oil prices to near $100 per barrel. This exacerbated market concerns over inflation and prompted investors to heavily sell off equity assets.

From Ms. Wood's overnight operations,She continues to implement an extremely ruthless 'weed out the weak and keep the strong' strategy:Completely divesting from pure medical hardware and outdated biotechnology that lack data barriers, while aggressively purchasing an Asian digital payment giant. She is also continuously building up concentrated positions at the intersection of AI healthcare and gene editing.

Buying direction: Aggressively acquiring Japanese digital payment giant PayPay

Ms. Wood aggressively acquired Japanese digital payment giant $PayPay (PAYP.US)$ with 275,000 shares. The company just listed on the U.S. stock market overnight, closing more than 13% higher on its first day. This is a highly strategic cross-market bet.

PayPay is no longer just a payment tool; behind it lies an enormous and high-frequency real consumer transaction database in Asia. In the AI era, possessing such a high-dimensional 'closed-loop data ecosystem' is equivalent to securing a ticket for the second half of the fintech game. ARK’s concentrated position is a high-probability wager on the potential monetization of high-frequency digital consumption scenarios and accumulated data.

Previously, it continued to aggressively increase its holdings in the gene-editing leader $CRISPR Therapeutics (CRSP.US)$ by 112,800 shares, while adding to its position in AI healthcare data ecosystem $Tempus AI (TEM.US)$ by 18,800 shares and genomics diagnostics company $GeneDx Holdings (WGS.US)$ by 52,100 shares.

ARK's ultimate blueprint in the healthcare sector has emerged. TEM and WGS control massive amounts of clinical and molecular data (fuel for AI), while CRSP holds the 'gene scissors' that rewrite life’s code from the ground up. This integration of 'precise design through foundational computing power' with 'gene editing' is revolutionizing the traditional trial-and-error drug development system and represents the most explosive non-linear growth trajectory today.

Sell-side action: Reduce positions in Circle on rallies

Cathie Wood slightly reduced her stake overnight in $Circle (CRCL.US)$ by over 10,000 shares; this company's stock has surged more than 86% since its earnings release. The market interpreted this rally as a positive reaction to the earnings — Circle achieved revenue of $770 million in Q4 2025, a year-over-year increase of 77%, with net profit reaching $133 million. However, what truly deserves attention is not these numbers themselves, but the structural changes behind them: as AI agents become new economic actors, the entire financial infrastructure logic needs to be rewritten.

Cathie Wood continued to sell shares overnight in single-cell sequencing giant $10x Genomics (TXG.US)$ by 18,400 shares, reducing her stake in life sciences tools company $Standard BioTools (LAB.US)$ 12,800 shares, as well as a precision medicine company $Personalis (PSNL.US)$ 6,850 shares.

This is in stark contrast to the heavy investment in TEM and CRSP on the buy-side. The growth ceiling for pure medical testing hardware lacking a core AI data ecosystem has become apparent. Capital is extremely astute and is rapidly withdrawing from 'pure tool' endpoints that are prone to red ocean price wars, shifting instead to embrace applications and data platforms capable of defining rules.

Previously, it also reduced its holdings in an RNA-targeted therapy company $Ionis Pharmaceuticals (IONS.US)$ by 43,500 shares. As foundational gene-editing technologies like CRISPR mature rapidly, some early RNA therapy targets are beginning to lose their relative advantage within ARK's portfolio—a routine capital rotation under the backdrop of technological iteration.

Futubull's [Opportunities Page] has launched a feature to track celebrity portfolio opportunities! Choose from multiple celebrity portfolios, one-click follow the moves of top investors, precisely lock in high-quality stocks, and invest with greater confidence!

324K Views